Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.

Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrman M, Hochhaus A, Hasford J, Hehlmann R, Saußele S; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK).

Ann Hematol. 2014 Jul;93(7):1167-76.

PMID:
24658964
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.

Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA, Lipton JH, Slovak ML, Appelbaum FR, Druker BJ.

Br J Haematol. 2014 Jan;164(2):223-32. doi: 10.1111/bjh.12618. Epub 2013 Nov 4.

PMID:
24383843
[PubMed - indexed for MEDLINE]
3.

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Saußele S, Hochhaus A.

J Clin Oncol. 2014 Feb 10;32(5):415-23. doi: 10.1200/JCO.2013.49.9020. Epub 2013 Dec 2.

PMID:
24297946
[PubMed - indexed for MEDLINE]
4.

High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.

Petzer AL, Wolf D, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Oucheva R, Ulmer H, Kwakkelstein M, Rancati F, Gastl G.

Haematologica. 2010 Jun;95(6):908-13. doi: 10.3324/haematol.2009.013979. Epub 2010 Feb 9.

PMID:
20145273
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.

Cerrano M, Crisà E, Pregno P, Aguzzi C, Riccomagno P, Boccadoro M, Ferrero D.

Am J Hematol. 2013 Oct;88(10):838-42. doi: 10.1002/ajh.23501. Epub 2013 Jul 23.

PMID:
23757199
[PubMed - indexed for MEDLINE]
6.
7.

Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.

Gotta V, Bouchet S, Widmer N, Schuld P, Decosterd LA, Buclin T, Mahon FX, Csajka C, Molimard M.

Leuk Res. 2014 Jul;38(7):764-72. doi: 10.1016/j.leukres.2014.03.023. Epub 2014 Apr 26.

PMID:
24844604
[PubMed - indexed for MEDLINE]
8.

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.

Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H.

Cancer. 2003 Sep 15;98(6):1105-13.

PMID:
12973833
[PubMed - indexed for MEDLINE]
Free Article
9.

Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.

Koh Y, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, Lee KH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Chung J, Shin HJ, Kim SH, Kim CS, Song HS, Kim MK, Hyun MS, Ahn JS, Jung CW, Park S; Korean Society of Hematology CML working party.

Ann Hematol. 2010 Jul;89(7):725-31. doi: 10.1007/s00277-010-0910-8. Epub 2010 Feb 24.

PMID:
20179930
[PubMed - indexed for MEDLINE]
10.

High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.

Petzer AL, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Stanchev A, Grubinger T, Kwakkelstein M, Schuld P, Gastl G, Wolf D.

Haematologica. 2012 Oct;97(10):1562-9. doi: 10.3324/haematol.2011.060087. Epub 2012 Apr 17.

PMID:
22511495
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX.

J Clin Oncol. 2014 Feb 10;32(5):424-30. doi: 10.1200/JCO.2012.48.5797. Epub 2013 Dec 9.

PMID:
24323036
[PubMed - indexed for MEDLINE]
12.

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.

Latagliata R, Ferrero D, Iurlo A, Cavazzini F, Castagnetti F, Abruzzese E, Fava C, Breccia M, Annunziata M, Stagno F, Tiribelli M, Binotto G, Mansueto G, Gozzini A, Russo S, Cavalli L, Montefusco E, Gugliotta G, Cedrone M, Russo Rossi A, Avanzini P, Pregno P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Storti S, D'Addosio A, Rege-Cambrin G, Luciano L, Alimena G.

Drugs Aging. 2013 Aug;30(8):629-37. doi: 10.1007/s40266-013-0088-6.

PMID:
23681399
[PubMed - indexed for MEDLINE]
13.

High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.

Thielen N, van der Holt B, Verhoef GE, Ammerlaan RA, Sonneveld P, Janssen JJ, Deenik W, Falkenburg JH, Kersten MJ, Sinnige HA, Schipperus M, Schattenberg A, van Marwijk Kooy R, Smit WM, Chu IW, Valk PJ, Ossenkoppele GJ, Cornelissen JJ.

Ann Hematol. 2013 Aug;92(8):1049-56. doi: 10.1007/s00277-013-1730-4. Epub 2013 Apr 10.

PMID:
23572137
[PubMed - indexed for MEDLINE]
14.

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.

Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes J.

Haematologica. 2012 Jul;97(7):1029-35. doi: 10.3324/haematol.2011.056721. Epub 2012 Jan 22.

PMID:
22271898
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.

Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G, Martinelli G, Baccarani M, Rosti G; GIMEMA CML Working Party.

Blood. 2009 Apr 9;113(15):3428-34. doi: 10.1182/blood-2007-08-103499. Epub 2009 Feb 11.

PMID:
19211938
[PubMed - indexed for MEDLINE]
Free Article
16.

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A.

Blood. 2014 Jan 23;123(4):494-500. doi: 10.1182/blood-2013-06-511592. Epub 2013 Dec 5.

PMID:
24311723
[PubMed - indexed for MEDLINE]
17.

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.

Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintás-Cardama A, Cortes J.

Blood. 2013 Jun 13;121(24):4867-74. doi: 10.1182/blood-2013-03-490128. Epub 2013 Apr 25.

PMID:
23620574
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.

Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E, Alimena G, Ehrencrona H, Hjorth-Hansen H, Kairisto V, Levato L, Martinelli G, Nagler A, Lanng Nielsen J, Ozbek U, Palandri F, Palmieri F, Pane F, Rege-Cambrin G, Russo D, Specchia G, Testoni N, Weiss-Bjerrum O, Saglio G, Simonsson B.

Blood. 2009 May 7;113(19):4497-504. doi: 10.1182/blood-2008-12-191254. Epub 2009 Mar 4.

PMID:
19264678
[PubMed - indexed for MEDLINE]
Free Article
19.

Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.

Zwaan CM, Rizzari C, Mechinaud F, Lancaster DL, Lehrnbecher T, van der Velden VH, Beverloo BB, den Boer ML, Pieters R, Reinhardt D, Dworzak M, Rosenberg J, Manos G, Agrawal S, Strauss L, Baruchel A, Kearns PR.

J Clin Oncol. 2013 Jul 1;31(19):2460-8. doi: 10.1200/JCO.2012.46.8280. Epub 2013 May 28.

PMID:
23715577
[PubMed - indexed for MEDLINE]
Free Article
20.

Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib.

Legros L, Guilhot J, Huault S, Mahon FX, Preudhomme C, Guilhot F, Hueber AO; French CML Group (FI-LMC).

Leuk Res. 2014 Jun;38(6):662-5. doi: 10.1016/j.leukres.2014.01.010. Epub 2014 Feb 1.

PMID:
24553365
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk